The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World

Table 4

Access limitations identified by respondents. Results are presented as N (%).

	North America	Europe	Elsewhere	p-value
	N=183	N=103	N=58
Access never limited for CD	103 (56%)	79 (77%)	16 (28%)	<0.001
Access never limited for UC	99 (54%)	76 (74%)	18 (31%)	<0.001
Access is sometimes limited in newly diagnosed CD	35 (19%)	12 (12%)	19 (33%)	0.005
Access is sometimes limited before failure of steroids or EEN followed by IM in CD	42 (23%)	13 (13%)	29 (50%)	<0.001
Access is sometimes limited except in hospitalized, steroid-refractory UC	20 (11%)	9 (9%)	12 (21%)	0.067
Access is sometimes limited in steroid-dependent UC before failure of steroids followed by an immunomodulator	41 (22%)	12 (12%)	23 (40%)	<0.001
Dosing regimen is sometimes limited	32 (17%)	9 (9%)	20 (34%)	<0.001
Duration of anti-TNF therapy is sometimes limited	5 (3%)	8 (8%)	5 (9%)	0.083
Access to day clinics for infusion is sometimes limited	14 (8%)	5 (5%)	6 (10%)	0.418